CytRx Announces FDA’s Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients

On January 20, 2015 CytRx Corporation reported that the United States Food and Drug Administration (FDA) has removed the partial clinical hold on the Company’s aldoxorubicin clinical trials (Press release CytRx, JAN 20, 2015, View Source [SID:1234501356]). Enrollment and dosing of new patients is now permitted after study sites’ Institutional Review Boards (IRBs) approve the revised trial protocols.

“CytRx developed modified study parameters intended to avoid potential risks, while allowing the company to evaluate the therapeutic impact of aldoxorubicin for patients with soft tissue sarcoma, glioblastoma, Kaposi’s sarcoma, and small cell lung cancer, among other trials,” said Steven A. Kriegsman, Chairman and CEO of CytRx. “Our staff worked closely with the FDA Oncology Division to resolve all partial clinical hold issues as rapidly as possible. We expect enrollment and dosing in the ongoing clinical trials to be back underway soon.”

CytRx currently believes that enrollment rates and timelines for its trials will remain materially unchanged. The Company expects to complete enrollment in its ongoing pivotal global Phase 3 trial in second-line soft tissue sarcoma by the end of 2015 and unblind the clinical data by mid-2016. Subject to FDA approval, CytRx’s market launch of aldoxorubicin for second line soft tissue sarcoma is projected to commence in 2017.

Eleison Pharmaceuticals Partners with Intelgen (HK) Limited to Develop and Commercialize ILC for the China Market

On January 19, 2015 Eleison Pharmaceuticals, Inc. ("Eleison"), a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, reported a partnership with Intelgen (HK) Limited ("Intelgen") to develop and commercialize the lung cancer drug candidate ILC (Inhaled Lipid-complexed Cisplatin) for the Chinese market (Press release, Eleison Pharmaceuticals, JAN 19, 2015, View Source [SID1234517398]). Mr. Edwin Thomas, CEO of Eleison Pharmaceuticals commented, "We are highly pleased to have as a partner Intelgen, an emerging pharmaceutical company in China and ideally capable of developing and commercializing ILC." Ms. Lan Zou, President and CEO of Intelgen commented, "ILC is potentially an important new treatment for lung cancer, and we look forward to working with Eleison to develop ILC for the benefit of patients with few therapeutic options." Under the terms of the partnership agreement, Intelgen received exclusive marketing rights in China and will be responsible for marketing and distribution of ILC in the China market. Eleison and Intelgen will work cooperatively for the clinical development and regulatory approval of ILC in China. Eleison has received an up-front payment, and will receive royalties, milestone payments, and development support from Intelgen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Karcinolys’ Myb34.5 oncolytic virus preclinical results in pancreatic cancer featured in peer-reviewed journal “Human Gene Therapy”

On January 19th, 2015 Karcinolys SAS, a privately-held biotechnology company developing the Myb34.5 oncolytic virus, reported that data from preclinical studies in pancreatic cancer models were featured in the peer-reviewed journal Human Gene Therapy (Press release, Karcinolys, JAN 19, 2015, View Source [SID1234525529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper titled "Targeted oncolytic HSV-1 eradicates experimental pancreatic tumours" was authored by Marion Gayral and Pierre Cordelier, Ph.D., Senior Scientist, INSERM U1037, Cancer Research Center of Toulouse and Université Paul Sabatier Toulouse III, and can be accessed at: View Source

The paper featured preclinical studies of the Myb34.5 oncolytic virus. The authors found that cellular transcription factor B-myb was present in experimental pancreatic ductal adenocarcinoma (PDAC) and tumours, and was over expressed in patients’ tumours, as compared to normal adjacent pancreas. Myb34.5 replicated to high level in human PDAC cell lines and not in adjacent normal tissues, and was associated with cell death by apoptosis. In experimental models of PDAC, mice receiving intratumoral Myb34.5 injections appeared healthy and tumour progression was inhibited, with evidences of tumour necrosis, haemorrhage, viral replication and cancer cell death by apoptosis. Combining standard-of-care chemotherapy with Myb34.5 successfully led to a very impressive antitumoral effect that is rarely achieved in this experimental model, and resulted in a greater reduction in tumour growth than chemotherapy alone.

"The publication of data from our lead compound, Myb34.5, in this respected peer-reviewed journal emphasizes the potential importance of Karcinolys’ oncolytic virus may have in oncology," said Jean-Luc Béjot, MD, MBA, Chief Executive Officer of Karcinolys. "As we plan to move Myb34.5 through the clinic in 2017, we will continue to share our findings with the medical community through peer-reviewed publications, increasing the exposure of our drug candidate and expanding partnering opportunities."

About Myb34.5

Myb34.5 is a replication-conditional oncolytic virus derived from herpes simplex virus type 1 (HSV-1) through targeted genetic engineering. The key mutation is the insertion of cellular transcription factor b-myb gene as a promoter gene sequence controlling and retargeting the expression of HSV-1 virulence gene gamma34.5 (?34.5). Replication of Myb34.5 in infected cells is conditioned by the expression of b-myb, which has been found to be over-expressed in pancreatic ductal adenocarcinoma cells. Myb34.5 selectively replicates in cancer cells, resulting in infected cancer cell death, while sparing normal surrounding tissue cells. Karcinolys in-licensed Myb34.5 from Massachusetts General Hospital (MGH, Harvard University, Boston, Ma., USA) in 2007. Myb34.5 was granted orphan drug designation by the FDA on December 23, 2014.

Xenetic Biosciences to Hold Business Update Conference Call January 20th

On January 16, 2016 Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, reported that it will hold a conference call on Tuesday, January 20, at 12:00 UK time, 7:00 a.m. ET. M. Scott Maguire, chief executive officer, and Colin Hill, chief financial officer and board member, will provide a business update and answer questions (Press release, Xenetic Biosciences, JAN 16, 2015, View Source [SID1234537815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, U.K.-based participants should call 0800 368 0649, and participants in all other locations should call +44 20 3059 8125. The participant password will be: Sciences. A telephone replay will be available for seven days following the call’s conclusion. Replay dial-in numbers are as follows: United Kingdom 0121 260 4861; United States 866-268-1947; and all other locations + 44 121 260 4861. Please provide conference ID 3245500# when accessing the replay. In addition, the call will be webcast and available at the Investor Relations section of www.xeneticbio.com in the "Events and Presentations" tab.

Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need

On January 16, 2015 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France (Press release, Hoffmann-La Roche , JAN 16, 2015, View Source [SID:1234513489]). Trophos’s proprietary screening platform generated olesoxime (TRO19622), which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a pivotal phase II clinical trial with olesoxime in SMA showed a beneficial effect on the maintenance of neuromuscular function in individuals with Type II and non-ambulatory Type III SMA, as well as a reduction in medical complications associated with the disease. These data were first presented in April 2014 at the annual meeting of the American Academy of Neurology (AAN).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This acquisition highlights Roche’s commitment to developing medicines for spinal muscular atrophy, a serious disease with no effective treatment," said Sandra Horning, M.D., Chief Medical Officer and Head of Global Product Development at Roche. "We will build on the work done by Trophos and the French Muscular Dystrophy Association to advance the development of olesoxime and to bring it to people who live with this devastating condition as quickly as possible."
Under the terms of the agreement, Trophos’s shareholders will receive an upfront cash payment of EUR 120 million, plus additional contingent payments of up to EUR 350 million based on achievement of certain predetermined milestones.
"SMA is a grievous disease with a huge impact on the daily life of patients and their families, who are currently left only with supportive care. We are proud to see the development of this medicine evolving, with the ultimate goal of a potential first medicine for SMA," said Christine Placet, Chief Executive Officer of Trophos. "This is a tremendous recognition of the work done by Trophos’s teams and supporters over the past 16 years."

About Spinal Muscular Atrophy (SMA)
SMA is a life-limiting and highly disabling genetic disease characterised by progressive muscle weakness and loss of motor function. SMA affects the motor neurons of the voluntary muscles used for activities such as crawling, walking, head and neck control and swallowing. Typically, SMA presents in early childhood and is the most common genetic cause of infant mortalityi. It is one of the most common rare diseases, with one in 6,000 to one in 10,000 children affected. SMA is an autosomal recessive genetic disease caused by a loss of function of the Survival Motor Neuron (SMN) 1 gene, which leads to insufficient levels of SMN protein, progressive deterioration of nerve cells in the spinal cord and loss of motor neurons. The mutated SMN1 gene responsible for SMA is carried by up to 20 million potential parents in the United States and European Union, most of them unaware that they are carriers.

Patients with SMA are usually categorised by having one of the four types of the disease, based on severity, the highest level of motor functioning achieved and time of onset:
Type I : The most severe form of SMA. Symptoms usually emerge within the first six months of life. Affected infants have low muscle tone, profound muscle weakness and impaired ability to move. Babies with type I SMA never sit. Simple tasks, such as holding up their heads, feeding and swallowing, can be very difficult. Progressive weakness of chest muscles increases the risk of respiratory infections and poor lung growth. Babies with type I SMA are at very high risk of irreversible decline in respiratory capacity. Type I SMA carries a high mortality rate, with more than half of all affected children not surviving beyond two years of age.

Type II : Intermediate form of SMA. Symptoms usually emerge between six and 18 months of age. Individuals with Type II SMA typically are able to sit, but cannot walk, have severe and progressive motor disability and often require care 24 hours a day for their whole life. Individuals with Type II often develop severe curvature of the spine (scoliosis) and weakness of the chest muscles leading to high risk of severe respiratory infections. The severity and progression of the disease varies from person to person, life expectancy ranges from early childhood to adulthood.

Type III : Symptoms can emerge anywhere between 18 months and early adulthood and include difficulty walking, muscle weakness and an increased risk of respiratory infections. A significant number of people with Type III SMA lose the ability to walk and can also develop severe scoliosis and other orthopaedic problems. Many patients become non-ambulatory and are wheelchair bound at the age of 40.

Type IV : Adult form of SMA. A less common form of SMA, this type affects adults and is characterised by a slower progression of symptoms that mainly affect the ability to walk. Symptoms typically emerg after the age of 35 and patients have a normal life expectancy.

About Olesoxime
Olesoxime (TRO19622) is an investigational medicine designed to protect the health of motor nerve cells. Results of a pivotal phase II study of olesoxime in Type II and non-ambulatory Type III SMA patients from the ages of three to 25 years were first presented in April 2014 at the 66th American Academy of Neurology (AAN), Philadelphia, PA, USA. Trophos’s development program was supported by the French Muscular Dystrophy Association. Olesoxime has been granted ‘Orphan Medicinal Product’ designation for the treatment of SMA by the European Medicines Agency and orphan drug designation by the US Food and Drug Administration.